Filing Flows › Precision Biosciences (DTIL) › Q2 FY26
Precision Biosciences (DTIL) Q2 FY26 earnings results (second quarter fiscal 2026)
10-K filed Mar 12, 2026
Precision Biosciences (DTIL) reported revenue of $34.2M for the second quarter fiscal 2026 (Q2 FY26), up 54-fold from a year earlier and up 2,631-fold from the quarter before. Operating margin was 36.6%, net earnings $20.1M (58.9% of revenue).
Precision Biosciences, Q2 FY26: revenue $34.2M (54× year over year), operating margin 36.6%, net earnings $20.1M, operating cash flow −$11.2M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $34.2M | 2,631× | 54× |
| Operating profit | $12.5M | — | — |
| Net earnings | $20.1M | — | — |
| Operating cash flow | −$11.2M | — | — |
What changed
Revenue was $34.2M in Q2 FY26, up 5261% year over year and up 263008% from the previous quarter.
Operating profit was $12.5M, a 36.6% margin (up 3930.9 points year over year). Total costs fell 15% while revenue rose 5261%. Net earnings were $20.1M. The effective tax rate was 0.0%. Non-operating items added $7.6M, 38% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$11.2M. Non-cash charges added back $345K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $33.8M. Capital expenditures of $19K exceeded it, leaving free cash flow of −$11.3M.
Questions
What was Precision Biosciences' revenue in the second quarter fiscal 2026?
Precision Biosciences (DTIL) reported revenue of $34.2M for the second quarter fiscal 2026 (Q2 FY26), up 54-fold from a year earlier and up 2,631-fold from the quarter before.
Was Precision Biosciences profitable in the second quarter fiscal 2026?
Operating profit was $12.5M (36.6% of revenue) and net earnings $20.1M.